Results 81 to 90 of about 15,824 (192)
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]
, 2020 Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Adedoyin, Adedayo +9 more
core +1 more source
Microbiology SpectrumWith the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang +13 more
doaj +1 more source
Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model [PDF]
Клиническая микробиология и антимикробная химиотерапияObjective. To study pharmacodynamics of meropenem alone and in combination with avibactam in an in vitro dynamic model; to evaluate effectiveness of meropenem against K.
Strukova E.N., golikova-mv.
doaj +1 more source
Activity of OP0595-β-lactam combination against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactama [PDF]
, 2015 Background: OP0595 is a diazabicyclooctane that (i) acts as a PBP2-ctive antibacterial, (ii) inhibits Class A and C β-lactamases and (iii), like mecillinam, gives β-lactamase-independent potentiation of β-lactams targeting other PBPs.
Livermore, David M. +3 more
core +1 more source
Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics
MicrobiologyOpen, Volume 15, Issue 1, February 2026.Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li +4 more
wiley +1 more source
Journal of XenobioticsBackground: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT Persistent Burkholderia cepacia bacteremia in soft tissue infections creates diagnostic and therapeutic challenges due to its resistance profile and potential for endovascular involvement. Early culture‐guided therapy, multidisciplinary coordination, and vigilance for complications, such as infective endocarditis, are essential for achieving ...
Chukwuka Elendu +5 more
wiley +1 more source
Frontiers in Cellular and Infection MicrobiologyIntroductionAcinetobacter baumannii is a leading cause of healthcare-associated infections in immunocompromised patients and frequently exhibits multidrug resistance.
Ilaria Cavallo +11 more
doaj +1 more source
Role of cephalosporins in the era of Clostridium difficile infection [PDF]
, 2016 The incidence of Clostridium difficile infection (CDI) in Europe has increased markedly since 2000. Previous meta-analyses have suggested a strong association between cephalosporin use and CDI, and many national programmes on CDI control have focused on ...
Brogard +12 more
core +2 more sources
Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.Background The global spread of carbapenemase‐producing Enterobacterales (CPE) has emerged as a significant public health challenge. However, epidemiological studies on CPE infections in Latin America remain scarce. This study aims to characterize bloodstream infections (BSIs) caused by CPE at a tertiary hospital over a 6‐year period and analyze the ...
Juan David Cáceres-González +6 more
wiley +1 more source